Wang Yaqin, Wang Tianxiao, Zhang Yuewei
Hepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, 102218, People's Republic of China.
Immunotargets Ther. 2024 Jul 4;13:343-348. doi: 10.2147/ITT.S470018. eCollection 2024.
Unresectable recurrent lymph node metastasis of colorectal cancer (CRC) is considered as an incurable disease clinically and has a very poor prognosis. Here, we report a male KRAS wild-type CRC case with a huge abdominal lymph node metastasis (12 cm in diameter) after CRC surgery. After three intratumoral injections of oncolytic virus (H101) combined with four cycles of low-dose oral capecitabine, the size of the metastatic lymph node shrank remarkably in response to the anticancer drug and a complete response (CR) was achieved with progression-free survival (PFS) of 19 months. The main adverse reaction was mild fever, which was relieved after physical cooling. The patient is in a general good condition now without any relapse of abdominal lymph node for over a year. On this basis, we propose that the combination therapy of oncolytic virus and capecitabine could be a promising clinical therapeutic strategy for unresectable recurrent lymph node metastasis in CRC patients.
结直肠癌(CRC)不可切除的复发性淋巴结转移在临床上被视为不治之症,预后非常差。在此,我们报告1例男性KRAS野生型CRC病例,该患者在CRC手术后出现巨大腹部淋巴结转移(直径12厘米)。在瘤内注射3次溶瘤病毒(H101)并联合4个周期的低剂量口服卡培他滨后,转移性淋巴结的大小因抗癌药物治疗而显著缩小,并实现了完全缓解(CR),无进展生存期(PFS)为19个月。主要不良反应为轻度发热,经物理降温后缓解。患者目前总体状况良好,腹部淋巴结在一年多的时间里未出现任何复发。在此基础上,我们提出溶瘤病毒与卡培他滨联合治疗可能是CRC患者不可切除复发性淋巴结转移一种有前景的临床治疗策略。